BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients

뉴스 본문을 불러오고 있어요.

BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients | 웨이프 WAPE

BeOne Medicines Announced At ESMO Saturday, Data Showing Investigational GPC3 x 4-1BB Bispecific Achieved 36% Confirmed Response Rate At Phase 3 Dose With Favorable Safety Profile In Heavily Pretreated Liver Cancer Patients

기사 요약

관련 종목

댓글 —